Pular para o conteúdo
Menu
Mix Vale

Artificial intelligence spearheads medical innovation, offering new hope for cancer treatment and disease discovery

Luís Pereira
Por 5 min de leitura
Compartilhe

Artificial intelligence is rapidly transforming the landscape of modern medicine, from customizing cancer therapies to identifying novel applications for existing medications. Researchers are leveraging advanced AI systems to analyze intricate microscopic images and pinpoint subtle biological indicators that human observation might easily miss, ushering in an era of unprecedented diagnostic and therapeutic precision.

Publicidade

While some of these cutting-edge technologies are already benefiting patients, others remain in various stages of clinical trials or laboratory research. This distinction is crucial for understanding the immediate impact versus the promising future of AI in healthcare. What scientists are achieving today was largely unimaginable just a few years ago, signaling a profound shift in how medical challenges are approached.

AI revolutionizes cancer therapy and drug discovery

The integration of artificial intelligence is fundamentally changing how medical professionals address complex diseases, particularly in oncology. By enabling a more personalized approach, AI algorithms can analyze individual patient data, including tumor characteristics, to recommend highly tailored treatment regimens. This precision medicine paradigm aims to maximize efficacy while minimizing adverse effects, moving beyond a one-size-fits-all model.

Publicidade

Beyond individual patient care, AI also plays a pivotal role in accelerating drug discovery and development. Its capacity to sift through vast datasets of biomedical information, analyze molecular structures, and predict drug interactions significantly shortens research timelines. This capability is particularly impactful in identifying new therapeutic pathways or repurposing existing compounds for different conditions, addressing critical gaps in treatment options.

Breakthrough in melanoma treatment with mRNA vaccine

One of the most significant recent advances comes from a collaborative effort between Moderna and Merck, who announced positive topline results from a Phase 3 trial for a personalized mRNA-based cancer vaccine. The study, involving 1,137 individuals with high-risk melanoma that had been surgically removed, tested intismeran autogene (also known as V940 or mRNA-4157) in combination with Keytruda.

The combination therapy successfully met its primary endpoint for recurrence-free survival and also achieved a key secondary endpoint measuring distant metastasis-free survival. This marks the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer treatment, representing a landmark achievement in oncology. The core principle behind this therapy is to train the patient’s immune system to recognize and attack cancer cells based on their unique genetic mutations.

  • Researchers obtain a sample of the patient’s tumor.
  • AI algorithms analyze the tumor’s unique mutations to select specific targets.
  • An individualized mRNA treatment is created, encoding up to 34 neoantigens.
  • The vaccine trains the immune system to identify these cancer-specific characteristics.

While these initial results are highly encouraging, it is important to note that only topline data has been released. The companies plan to present the full findings at an international medical conference and share them with regulatory bodies. The study is also continuing to track overall survival outcomes. Earlier Phase 2b data, involving a smaller patient group with longer follow-up, indicated that intismeran plus Keytruda reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared to Keytruda alone. Despite the promising findings, intismeran remains an investigational therapy and has not yet received approval from the U.S. Food and Drug Administration (FDA) for melanoma treatment.

Repurposing existing drugs for underserved diseases

Developing new medications is a lengthy and resource-intensive process, prompting another research avenue: identifying new uses for existing, approved drugs. Dr. David Fajgenbaum co-founded the nonprofit Every Cure with this exact mission. The organization highlights a critical disparity: out of approximately 18,000 recognized diseases globally, only about 4,000 have FDA-approved treatments, leaving a vast number of conditions with limited or no therapeutic options.

Publicidade

Every Cure employs AI to systematically scan vast repositories of biomedical knowledge, searching for unexpected connections between approved medicines and other diseases they might effectively treat. This AI-driven system can generate tens of millions of potential drug-disease predictions in less than a day, a scale impossible for human researchers. The most promising candidates are then prioritized for further laboratory and clinical validation.

The federal Advanced Research Projects Agency for Health (ARPA-H) supports this innovative approach through its MATRIX project. MATRIX utilizes machine learning and AI to predict which FDA-approved drugs could be repurposed. While AI does not definitively prove a drug’s efficacy for a new illness, it dramatically narrows the search space, guiding researchers to the most promising leads. Fajgenbaum’s own experience with multicentric Castleman disease, where an existing blood disorder drug (ruxolitinib) provided remission, underscores the profound impact of finding new uses for established treatments, even if AI wasn’t directly involved in his specific case. This personal story fuels Every Cure’s ambition to scale such discoveries using AI.

AI enhances fertility treatments with advanced sperm analysis

Artificial intelligence is also tackling challenges in reproductive medicine, as demonstrated by the Sperm Tracking and Recovery (STAR) system developed at the Columbia University Fertility Center. This innovative platform integrates high-speed imaging with an AI detection model and microfluidics to analyze semen samples with unprecedented detail and efficiency.

The STAR system is specifically designed to assist patients diagnosed with azoospermia or cryptozoospermia, conditions characterized by the apparent absence or extremely low numbers of sperm. Manual examination of these samples is labor-intensive and prone to missing rare sperm cells. In contrast, STAR can capture and process approximately 1.1 million images every hour, with its AI model meticulously scanning each frame for potential sperm cells, significantly improving the chances of successful sperm retrieval for fertility treatments.

Publicidade

Luís Henrique Costa é jornalista formado pela FMU, editor-chefe e fundador do Mix Vale, portal de notícias em atividade desde 2011. Responde pela direção editorial do veículo, que cobre Brasil e mundo em economia, benefícios sociais, esportes, tecnologia, ciência e entretenimento. Atua na área há mais de 15 anos e lidera uma equipe de cerca de 15 colaboradores.

Notícias relacionadas

Mais lidas

  1. Ciência

    Meteoro no Nordeste: bólido cruza o céu de cinco estados às 21h34 e mobiliza buscas por fragmentos na Paraíba

  2. Caixa Econômica Federal

    Pé-de-Meia paga parcela de R$ 1.000,00 a aprovados no ensino médio de 2026 entre fevereiro e março de 2027

  3. Política

    Com obstrução parcial no intestino, Jair Bolsonaro é internado no hospital DF Star em Brasília

  4. INSS

    Recuperação da senha Gov.br pelo celular exige reconhecimento facial ou código por SMS para o Meu INSS

  5. EUA

    Terremoto em Los Angeles atinge magnitude 4,2 e causa tremores leves em Commerce na madrugada

  6. Matéria Publicitária

    MineMV é o novo jogo grátis de construir com blocos; veja como jogar e liberado para todas as idades

  7. Política

    Regulamentação da escala 5×2 pelo governo encarece cálculo da hora extra a partir de 16 de dezembro

  8. Santa Catarina

    Acidente de trânsito na SC-108 envolve carro e moto e deixa motociclista morto em São Ludgero

  9. Mundo

    Jornalista italiano Corrado Augias morre aos 91 anos; presidente da Itália lamenta a perda

  10. Loterias

    Rendimento de R$ 40 milhões da Mega-Sena 3088 chega a R$ 337 mil por mês no Tesouro Direto